Results 81 to 90 of about 21,216 (279)

Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration [PDF]

, 2017
Objectives The site of pharmacological activity of raltegravir is intracellular. Our aim was to determine the extent of raltegravir cellular penetration and whether raltegravir total plasma concentration (Ctot) predicts cellular concentration (Ccell ...
Biollaz, Jérôme, Buclin, Thierry, Cavassini, Matthias, Colombo, Sara, Cruchon, Sandra, Decosterd, Laurent A., Fayet Mello, Aurélie, Franc, Claudia, Guignard, Nicole, Telenti, Amalio   +9 more
core  

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors [PDF]

, 2017
Objectives To characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November 16, 2016 in the Veneto region (Italy), where all drugs included in
Alvarez, M, Andreis, S, Andreoni, M, Antonelli, G, Basso, M, Boldrin, C, Cruciani, M, Dal Bello, F, Ferretto, R, Francavilla, E, Manfrin, V, Mengoli, C, Palù, G, Panese, S, Parisi, Sg., Rossi, Mc, Sarmati, L, Scaggiante, R, Turriziani, O   +18 more
core   +1 more source

Impact on weight of a Doravirine switch in people living with HIV

HIV Medicine, Volume 27, Issue 1, Page 136-145, January 2026.
Abstract Background and Objective Doravirine is among the first‐line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti‐integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we
Nina Garofoli, Philippe Flandre, Jean‐Paul Vincensini, Quentin Richier, Priscille Couture, Karine Lacombe, Gilles Pialoux, Jean‐Luc Meynard   +7 more
wiley   +1 more source

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy

Infection and Drug Resistance, 2010
Charlotte Charpentier1, Laurence Weiss21Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Université Paris-Diderot, Paris, France; 2Assistance Publique-Hôpitaux de ...
Charlotte Charpentier, Laurence Weiss
doaj  

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not

Retrovirology, 2011
Background HIV-2 is endemic in West Africa and has spread throughout Europe. However, the alternatives for HIV-2-infected patients are more limited than for HIV-1.
Damond Florence, Collin Gilles, Storto Alexandre, Charpentier Charlotte, Delelis Olivier, Ni Xiao-Ju, Descamps Diane, Mouscadet Jean-François   +7 more
doaj   +1 more source

Identification of Influenza PA_N Endonuclease Inhibitors via 3D-QSAR Modeling and Docking-Based Virtual Screening

Molecules, 2021
Structural and biochemical studies elucidate that PAN may contribute to the host protein shutdown observed during influenza A infection. Thus, inhibition of the endonuclease activity of viral RdRP is an attractive approach for novel antiviral therapy. In
Chao Zhang, Junjie Xiang, Qian Xie, Jing Zhao, Hong Zhang, Erfang Huang, Pangchui Shaw, Xiaoping Liu, Chun Hu   +8 more
doaj   +1 more source

Brief Report: Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008–2018

Journal of Acquired Immune Deficiency Syndromes, 2019
Background: The indisputable benefits of antiretroviral therapy (ART) in the reduction of mother-to-child-transmission of HIV have to be carefully balanced with the risks of embryo–fetal toxicities due to fetal exposure to maternal ART. The recent report
V. Rasi, M. Cortina-Borja, H. Peters, Rebecca Sconza, C. Thorne   +4 more
semanticscholar   +1 more source

Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial

Antimicrobial Agents and Chemotherapy, 2020
A population pharmacokinetic model was developed to explore the pharmacokinetics modification of unbound raltegravir during pregnancy. The RalFe ANRS160 study was a nonrandomized, open-label, multicenter trial enrolling HIV-infected pregnant women ...
Yi Zheng, D. Hirt, Sandrine Delmas, Gabrielle Lui, S. Benaboud, Jerome Lechedanec, J. Treluyer, C. Chenevier-Gobeaux, Elisa Arezes, A. Gelley, I. Amri, S. Urien, N. Bouazza, F. Foissac, J. Warszawski, J. Ghosn   +15 more
semanticscholar   +1 more source

EBV+ and Kaposi’s Sarcoma Herpesvirus‐Associated Multicentric Castleman Disease in a Patient With HIV Infection: A Case Report

Case Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Multicentric Castleman disease is a rare proliferative disease of lymphoid tissue. It has rarely been reported in Asian countries, particularly in HIV‐positive patients. Here, we report a case of Kaposi’s sarcoma herpesvirus‐associated Multicentric Castleman disease (KSHV‐MCD).
Mai-Yin Huang, Zhe Li, Wei Zhang, Hai-Yun Chen, Jun Liu, Chong-Xi Li, Priya Gusain   +6 more
wiley   +1 more source

Designing of Promising VEGFR‐2 Inhibitors by Using QSAR Modeling, Molecular Docking, and Molecular Dynamic Simulation: Implications Toward the Treatment of Cancer

Journal of Chemistry, Volume 2026, Issue 1, 2026.
Background The vascular endothelial growth factor receptor 2 (VEGFR‐2) is considered one of the most studied therapeutic targets for the treatment of various cancers. Among many heterocyclic compounds, the oxadiazole derivatives have been reported to exhibit significant anticancer activities. Therefore, exploring these derivatives against VEGFR‐2 could
Aisha A. Alsfouk, Pervaiz Ali Channar, Muhammad Sajjad Bilal, Syeda Abida Ejaz, Song J. A. Kim, Sohini Basu Roy   +5 more
wiley   +1 more source